Myeloma
The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
Advertisement
Drs. Rossi and Khouri discuss two presentations on the effects of selinexor exposure on CAR-T outcomes in multiple myeloma.
The agent is a first-of-its-kind, orally available, selective inhibitor of the nuclear export protein exportin 1.
The new indication for daratumumab and hyaluronidase-fihj plus D-VRd is based on results from the phase II CEPHEUS study.
MRD negativity is a strong predictor of better prognosis and survival in patients with MM.
Ongoing detection of TP53 mutations remains critical for accurate risk stratification and treatment planning in MM.
Patients with double-hit or triple-hit MM had significantly poorer outcomes compared to those with single-hit MM.
Advertisement
Novel agents such as belantamab mafodotin may improve PFS in patients with relapsed MM after anti-CD38 treatment.
Anito-cel showed "robust" efficacy in patients with relapsed or refractory multiple myeloma.
Myeloma in remission did not appear to affect myocardial infarction outcomes, but did affect resource utilization.
The latest data update on teclistamab in multiple myeloma continues to support strong efficacy and durable response.
The addition of daratumumab improved the performance of VRd in patients with newly diagnosed multiple myeloma.
The bispecific antibody was administered as a fourth-line treatment 12 years after the patient’s diagnosis.
Prior to the retrospective study presented at SOHO 2024, no study conducted a similar comparison of Dara-VTD and RVD.
The phase III KarMMa-9 trial will review the efficacy of R maintenance alone versus with ide-cel in newly diagnosed MM.
Prior research suggested that weekly carfilzomib at a dose of 70 mg/m2 plus dexamethasone can increase PFS.
The addition of daratumumab to VRd induction and consolidation induced higher rates of MRD negativity.
A single tocilizumab dose prior to initiation of teclistamab therapy effectively reduced the incidence of CRS.
Treatment with CELMoDs showed promising efficacy but high rates of neutropenia in patients with multiple myeloma.
Cilta-cel improved outcomes versus standard or care in myeloma, with a safety profile consistent with CAR-T therapies.
“Blood Cancer Talks" hosts are joined by Timothy Schmidt, MD, to discuss quadruplet therapy for myeloma.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.